Efavaleukin alfa
Sponsors
Amgen
Conditions
Active Systemic Lupus ErythematosusChronic Graft Versus Host Disease cGVHDInflammatory DiseasesRheumatoid Arthritis RASystemic Lupus ErythematosusUlcerative Colitis
Phase 1
Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis
TerminatedNCT03410056
Start: 2018-05-22End: 2020-05-13Updated: 2021-06-22
Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease
TerminatedNCT03422627
Start: 2018-04-27End: 2022-10-13Updated: 2023-11-22
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus Erythematosus
CompletedNCT03451422
Start: 2018-04-10End: 2021-10-12Updated: 2023-07-19
Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian Participants
CompletedNCT04987333
Start: 2021-08-09End: 2022-10-03Updated: 2024-03-29
Phase 2
Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus
TerminatedNCT04680637
Start: 2021-05-06End: 2023-05-22Updated: 2024-06-28
Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis
TerminatedNCT04987307
Start: 2022-01-31End: 2024-10-22Updated: 2026-01-13
Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis
TerminatedNCT05672199
Start: 2023-04-28End: 2024-10-31Updated: 2025-10-15